493 related articles for article (PubMed ID: 25278509)
1. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
4. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
5. [Bisphosphonates and breast cancer].
Vehmanen L; Saarto T
Duodecim; 2010; 126(10):1229-37. PubMed ID: 20597352
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
Costa L
Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature.
Liu Y; Zhao S; Chen W; Hu F; Zhu L; Zhang Q; Zhao Y
Clin Breast Cancer; 2012 Aug; 12(4):276-81. PubMed ID: 22622199
[TBL] [Abstract][Full Text] [Related]
8. On the horizon: can bisphosphonates prevent bone metastases?
Coleman R
Breast; 2007 Dec; 16 Suppl 3():S21-7. PubMed ID: 17988867
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
10. The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany.
Fick EM; Katalinic A; Waldmann A
Cancer Res Treat; 2015 Oct; 47(4):747-56. PubMed ID: 25672584
[TBL] [Abstract][Full Text] [Related]
11. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Gnant M
Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancer.
Hadji P; Kyvernitakis J; Albert U; Jockwig J; Kostev K
Int J Clin Pharmacol Ther; 2014 May; 52(5):352-9. PubMed ID: 24691062
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
Li J; Rugo HS
Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference.
Costa L
Curr Opin Support Palliat Care; 2014 Dec; 8(4):414-9. PubMed ID: 25319273
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
16. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
17. [The successful development of bisphosphonates in the therapy of osteoporosis].
Fassbender WJ; Stumpf UC; Kurth A
Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
[TBL] [Abstract][Full Text] [Related]
19. Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.
Enright K; Clemons M; Chow E
Support Care Cancer; 2004 Jan; 12(1):48-52. PubMed ID: 14577020
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for breast cancer: questions answered, questions remaining.
Layman R; Olson K; Van Poznak C
Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
